- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04522739
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease (STAND)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In 2018, 5.5 million older adults in the United States were diagnosed with Alzheimer's disease, and it is predicted that 15 million people will be diagnosed with dementia, including Alzheimer's disease by 2060. Older African Americans adults are more likely to be diagnosed with Alzheimer's disease as compared to Whites. Research search studies on high blood pressure show that African Americans have higher levels of the hormone aldosterone that can be involved with regulation of blood pressure and blood vessels. Research studies also show that changes in blood vessels in the brain from higher aldosterone levels are related to changes in thinking skills and memory (cognition). Spironolactone is a drug that blocks aldosterone and has been used to treat high blood pressure for 60 years. More recently, this drug has shown to have the potential to decrease declines in thinking skills and memory.
Spironolactone is widely used in clinical practice and is well-tolerated by younger and older persons. As such, this study is designed to learn how a small group of older African American adults with mild cognitive impairment will tolerate the drug. Persons who are eligible for the study and agree to participate will receive spironolactone or a placebo and be monitored for drug side effects for one year.
During the study, the researchers will monitor changes in thinking and memory and blood vessel stiffness, in addition to side effects that may be related to the drug. Study tests include questionnaires that evaluate thinking skills and memory, and an ultrasound that measures the stiffness of blood vessels in the neck which deliver blood to the brain. The thinking and memory tests and ultrasound will be performed at the beginning of the study, then repeated at the end of the study.
The results of this study can justify a larger size study of spironolactone in older African Americans with mild cognitive impairment. The study has the potential to identify a new use for a well-known drug that is safe and widely used in current clinical practice. Further, the results from this study can address a racial difference in Alzheimer's disease and preserve the health of the brain as people age.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Antoine Trammell, MD, MPH
- Phone Number: 404-712-6332
- Email: antoine.trammell@emory.edu
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Recruiting
- Emory clinic at Executive Park
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed and dated informed consent form
- Willingness to comply with all study procedures and availability for the duration of the study
- Self-identified African American
Blood pressure (BP) and hypertension criteria: normotensive and hypertensive participants will be eligible
- Normotensive criteria: BP 110-140/40-90 mmHg and not receiving any treatment for hypertension
- Hypertensive criteria: only controlled hypertensives will be eligible with BP range as in the normotensive criteria of 110-140/40-90 mmHg
MCI defined as:
- Subjective memory concern
Abnormal memory function per the Logical Memory subscale (Delayed Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale-Revised (the maximum score is 25):
- Score <11 for 16 or more years of education
- Score <9 for 8-15 years of education
- Score <6 for <7 years of education
- Montreal Cognitive Assessment (MoCA) score 15-25
- Preserved general functional performance per Functional Assessment Questionnaire (FAQ)<9
Exclusion Criteria:
- History of stroke in the previous three years
- MOCA<15 or the inability to follow instructions to perform cognitive testing
- Inability to participate in the study procedures: cognitive tests (communication limitations from language or other factors)
- Active medical problem/symptom that interferes with the study procedures, e.g., chest pain, shortness of breath, or abdominal pain
- Deemed ineligible by study investigators due to safety issues or non-compliance
- History of the inability to tolerate treatment with an aldosterone antagonist
Hypertension
- Uncontrolled defined as a BP > 140/90 mmHg
- Current therapy with RAAS modulating medications, i.e., angiotensin II receptor blocker (ARB), angiotensin converting enzyme inhibitor (ACEi), renin inhibitor, or aldosterone antagonist such as eplerenone (Inspra) due to the risk of hyperkalemia and the interference with the renin angiotensin aldosterone system (RAAS) system
- Renal disease (baseline creatinine > 2.0 mg/dL)
- Hyperkalemia (K+ > 5.5 milliequivalent (mEq)/dL)
- Other neurological or psychiatric conditions that could impact cognition, e.g., Parkinson's disease and related movement disorders, multiple sclerosis, epilepsy, or schizophrenia, untreated major depressive disorder, and other psychotic disorders
- Abnormal thyroid stimulating hormone (TSH) (>10 milliunits (mU)/L) or vitamin B12 (<250 pg/mL) as they can impact cognitive function. If the potential participant's TSH and/or vitamin B12 levels are abnormal, then the PI may enroll that person if it is thought the lab abnormalities are unrelated and do not affect cognitive function
- Active medical or psychiatric disease, which in the judgment of the study investigators affects participant safety or the scientific integrity of the study
- Uncontrolled congestive heart failure reflected by poor exercise tolerance and shortness of breath
- Women of childbearing potential, i.e., non-menopausal
- When potential participants are not capable of providing informed consent due to their cognitive impairment and a study partner/surrogate is not available to sign consent forms on their behalf
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Spironolactone
Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive spironolactone for 12 months.
|
The initial dose of spironolactone will be 25mg and will be increased to 50 mg after 2 weeks provided the following criteria are present: 1) systolic blood pressure (SBP) >110 mm Hg, 2) diastolic blood pressure (DBP) > 60 mm Hg, and no reported symptoms of hypotension (dizziness or weakness).
Participants will take one capsule by mouth per day.
Other Names:
|
Placebo Comparator: Placebo
Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive a placebo to match spironolactone for 12 months.
|
A placebo to match spironolactone will be taken orally once per day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Count of Adverse Events
Time Frame: Year 1
|
The safely of the study treatment will be assessed with the number of adverse events experienced in each study arm.
|
Year 1
|
Attrition rate
Time Frame: Year 1
|
The tolerability of the study treatment will be assessed by the attrition rate of participants in each study arm.
|
Year 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Trail Making Test Part A Score
Time Frame: Baseline, Month 6, Month 12
|
In Part A of the Trail Making Test (TMT) participants are presented with a sheet of paper with 25 circles numbered 1 through 25.
Participants are asked to draw lines connecting the circles in ascending order of the numbers.
The task is scored as the amount of time it takes in seconds for the circles to be correctly connected.
The average time to complete the task is 29 seconds.
Times greater than 78 seconds indicate cognitive impairment.
|
Baseline, Month 6, Month 12
|
Change in Trail Making Test Part B Score
Time Frame: Baseline, Month 6, Month 12
|
Part B of the Trail Making Test (TMT) includes a sheet of paper with circles with numbers (1-13) and letters (A-L).
Participants are asked to draw lines connecting the circles in ascending order of the numbers and letters, alternating between numbers and letters.
The task is scored as the amount of time it takes in seconds for the circles to be correctly connected.
The average time to complete the task is 75 seconds.
Times greater than 273 seconds indicate cognitive impairment.
|
Baseline, Month 6, Month 12
|
Change in Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall Score
Time Frame: Baseline, Month 6, Month 12
|
In the HVLT-R recall task, there are three trials where participants hear 12 words which they are asked to recall.
The Total Recall score is the sum of correct responses over the three trials.
Total scores range from 0 to 36 where higher scores indicate better recall.
|
Baseline, Month 6, Month 12
|
Change in Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall Score
Time Frame: Baseline, Month 6, Month 12
|
In the HVLT-R delayed recall task, participants hear 12 words and are asked to recall the words after waiting 20-25 minutes.
The score is the sum of correctly recalled words and the score ranges from 0 to 12, where higher values indicate better delayed recall.
|
Baseline, Month 6, Month 12
|
Change in Hopkins Verbal Learning Test-Revised (HVLT-R) Recognition Discrimination Index Score
Time Frame: Baseline, Month 6, Month 12
|
In the HVLT-R recognition task, participants hear 24 words (half of which they have heard before) and are asked each each word has been previously presented.
The recognition discrimination is calculated as the number of true positives minus the number of false positives during the recognition task.
Index scores can range from -12 to 12 with higher scores indicating better recognition discrimination.
|
Baseline, Month 6, Month 12
|
Change in Digit Span Test Score
Time Frame: Baseline, Month 6, Month 12
|
The Digit Span test being used is a subtest of the Wechsler Adult Intelligence Scale - Third Edition (WAIS-III) and assesses immediate memory and attention.
Participants are asked to repeat strings of numbers forwards and backwards.
The score is the number of digits that are repeated correctly.
Higher scores indicate improved memory and attention.
|
Baseline, Month 6, Month 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Antoine Trammell, MD, MPH, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Cognition Disorders
- Alzheimer Disease
- Cognitive Dysfunction
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Natriuretic Agents
- Diuretics
- Hormone Antagonists
- Mineralocorticoid Receptor Antagonists
- Diuretics, Potassium Sparing
- Spironolactone
Other Study ID Numbers
- STUDY00000124
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Spironolactone
-
Medical University of South CarolinaWithdrawnHidradenitis Suppurativa
-
Medical University of South CarolinaWithdrawn
-
Columbia UniversityCompletedHeart FailureUnited States
-
Asan Medical CenterCompletedHeart FailureKorea, Republic of
-
Yonsei UniversityWithdrawn
-
Instituto Nacional de Ciencias Medicas y Nutricion...TerminatedPatients With Fungic InfectionsMexico
-
Assistance Publique - Hôpitaux de ParisSociété de Dermatologie FrançaiseCompletedCutaneous Atrophy Due to CorticosteroidsFrance
-
State University of New York - Upstate Medical...WithdrawnEnd Stage Renal Disease | Congestive Heart FailureUnited States
-
Hebei Medical UniversityTerminatedHeart Failure, CongestiveChina
-
US Department of Veterans AffairsCompleted